PARP Inhibitors for Cancer Therapy

Ken Y. Lin, W. Lee Kraus

Research output: Contribution to journalShort surveypeer-review

76 Scopus citations


Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.

Original languageEnglish (US)
Pages (from-to)183
Number of pages1
Issue number2
StatePublished - Apr 6 2017
Externally publishedYes

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'PARP Inhibitors for Cancer Therapy'. Together they form a unique fingerprint.

Cite this